Top Page
Genflow Biosciences Plc
(LSE:GENF)
Genflow Biosciences Plc (GENF) vs. iShares MSCI United Kingdom ETF (EWC)
Genflow Biosciences Plc Business Overview & Revenue Model
Genflow Biosciences Plc Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -150.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -150.95K | -1.20K | -1.03K | -130.00 | 0.00 | 0.00 |
| EBITDA | -1.27M | -1.59M | -1.80M | -1.33M | -988.10K | -1.09K |
| Net Income | -1.27M | -1.59M | -1.63M | -1.34M | -988.29K | -651.01K |
Balance Sheet | ||||||
| Total Assets | 468.38K | 385.91K | 1.07M | 2.62M | 276.55K | 283.78K |
| Cash, Cash Equivalents and Short-Term Investments | 279.44K | 278.68K | 683.97K | 2.36M | 224.00K | 254.23K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 771.38K | 788.92K | 345.74K | 250.99K | 221.43K | 64.80K |
| Stockholders Equity | -303.00K | -403.01K | 725.91K | 2.37M | 55.12K | 218.98K |
Cash Flow | ||||||
| Free Cash Flow | -1.28M | -1.08M | -1.66M | -1.37M | -747.38K | -439.46K |
| Operating Cash Flow | -1.28M | -1.08M | -1.66M | -1.37M | -747.38K | -439.46K |
| Investing Cash Flow | 372.00 | 0.00 | -2.44K | -2.48K | 198.50K | 216.55K |
| Financing Cash Flow | 865.22K | 656.63K | 0.00 | 3.50M | 783.71K | 1.96M |
Genflow Biosciences Plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £9.38M | -3.80 | -648.46% | ― | ― | ― | |
47 Neutral | £28.99M | -5.93 | -202.14% | ― | ― | 23.76% | |
45 Neutral | £4.30M | -1.58 | -53.79% | ― | ― | 85.56% | |
45 Neutral | £864.14K | -1.58 | -85.21% | ― | 44.32% | 60.00% | |
43 Neutral | £6.14M | -5.54 | -433.59% | ― | ― | ― | |
41 Neutral | £3.08M | -0.28 | ― | ― | 418.49% | 27.86% |
Genflow Biosciences Plc Corporate Events
Genflow Biosciences Plc announced the successful completion of the dosing phase in their canine gene therapy trial, with no adverse events reported, indicating a strong safety profile. The trial, which began in March 2025, aims to assess the efficacy of their SIRT6-based gene therapy in extending healthspan, with initial results expected in January 2026 and further assessments in mid-2026. The company plans to explore early-stage licensing opportunities with animal health companies based on the efficacy data.
Genflow Biosciences Plc announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, a major global investment event in the healthcare sector. This participation is seen as a strategic move to engage with potential partners and investors as Genflow advances its gene-therapy pipeline, particularly focusing on lipid nanoparticle delivery for mRNA SIRT6 therapeutics, which could open new opportunities in the longevity space.
Genflow Biosciences Plc announced that as of 31 October 2025, the company’s total issued share capital consists of 493,547,942 Ordinary Shares, all with voting rights. This information is crucial for shareholders to determine their notification requirements under the Financial Conduct Authority’s rules, potentially impacting investment decisions and stakeholder engagement.
Genflow Biosciences Plc announced the publication of its second European patent application for a SIRT6 gene variant targeting non-alcoholic steatohepatitis (NASH), marking a significant milestone in its intellectual property portfolio. This development strengthens Genflow’s IP leadership in the longevity and metabolic disease space, establishing a robust European patent framework that supports its therapeutic platform and future clinical programs, thereby enhancing partnership potential and long-term value creation.
Genflow Biosciences Plc announced that the European Patent Office has recognized the patentability of its SIRT6 variant patent, marking a significant milestone in its intellectual property strategy. This development provides provisional protection across participating EPO member states, positioning Genflow to benefit from EU grant opportunities and strengthening its leverage in partnerships with pharmaceutical and biotech companies. The formal recognition of this patent underscores Genflow’s progress in securing its intellectual property and enhances its strategic position for future collaborations and funding.
Genflow Biosciences Plc has successfully administered its proprietary SIRT6-centenarian gene therapy for the second time in a clinical trial involving elderly dogs, demonstrating excellent safety and tolerability. This milestone highlights the potential of Genflow’s gene therapy platform to extend beyond human health into the lucrative global animal health market, with plans to advance its animal health initiative further. The company is committed to leveraging its innovative gene therapy platform to create value for shareholders and establish partnerships in the field of genetic longevity therapeutics.
Genflow Biosciences Plc has decided to terminate a previously announced subscription and instead raised £440,000 through an alternative transaction involving the issuance of 40 million new ordinary shares to CEO Eric Leire. This decision was made as the alternative is more favorable and less dilutive for shareholders. The new shares will be admitted to trading on the London Stock Exchange, with a total of 493,547,942 shares in issue post-admission. This move reflects confidence in Genflow’s mission to advance its gene therapy programs, with the additional capital supporting near-term objectives.